ADVISORY, Oct. 21, 2010 (GLOBE NEWSWIRE) --
What:
Intellipharmaceutics International Inc. (IPCI) will visit the NASDAQ MarketSite in New York City's Times Square.
In honor of the occasion, Dr. Isa Odidi, Chief Executive Officer of Intellipharmaceutics International Inc. (IPCI), will ring the NASDAQ Opening Bell.
Where:
NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Friday, October 22nd, 2010 at 9:15 a.m. to 9:30 a.m. ET
Contact:
Glenn Neumann
(416) 798-3001
gneumann@intellipharmaceutics.com
NASDAQ MarketSite:
Robert Madden
(646) 441-5045
Robert.Madden@NASDAQOMX.com
Feed Information:
The Opening Bell is available from 9:20 a.m. to 9:35 a.m. on AMC3 / C22, 87 degrees West, downlink frequency 4140 vertical. The feed can also be found on Ascent fiber 1623. If you have any questions, please contact Robert Madden at (646) 441-5045.
Radio Feed:
An audio transmission of the Opening Bell is also available from 9:20 a.m. to 9:35 a.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Ascent fiber 1623 as well.
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
For news tweets, please visit our Twitter page at:
Webcast:
A live webcast of the NASDAQ Opening Bell will be available at:
Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About Intellipharmaceutics International Inc. (IPCI):
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel or generic controlled release and targeted release oral solid dosage drugs. The Company's patented Hypermatrix(tm) technology is a unique and validated multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology, Intellipharmaceutics has a pipeline of products in various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, pain and infection. The Company has three products under review with the FDA for the purpose of obtaining regulatory approval.
Intellipharmaceutics' lead generic product under development is Dexmethylphenidate XR (dexmethylphenidate hydrochloride), a generic version of Focalin XR(R), which is an extended-release capsule for the treatment of Attention Deficit Hyperactivity Disorder. In 2008, Focalin(R), including Focalin XR(R), had U.S. sales of approximately U.S. $350 million. Intellipharmaceutics' generic products under review with the FDA also include generic versions of Protonix DR and Effexor XR.
Intellipharmaceutics' lead non-generic product under development is Rexista(TM) oxycodone, an abuse- and alcohol-deterrent controlled-release oral formulation of controlled-release oxycodone hydrochloride for the relief of pain. Rexista(TM) oxycodone is a unique dosage form designed to be deterrent to some of the well-documented abuses associated with currently marketed oxycodone products, such as abuse of these drugs by nasal inhalation when crushed or powdered and by injection when combined with solvents. Rexista(TM) oxycodone is also designed to resist release of the entire dose when consumed with alcohol, a significant problem with some opioid drugs. In 2008, oxycodone had U.S. sales of approximately U.S. $2 billion.
The Intellipharmaceutics International Inc. logo is available at
About NASDAQ OMX:
The NASDAQ OMX Group, Inc. is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, with approximately 3,600 listed companies. NASDAQ OMX offers multiple capital raising solutions to companies around the globe, including its U.S. listings market, NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX First North, and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and exchange-traded funds. NASDAQ OMX technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit. Please follow NASDAQ OMX on Facebook () and Twitter ().
NDAQA